Posted 4/5/2024
The first conference held under the auspices of Frederick National Laboratory’s (FNL’s) Scientific Standards Hub , an...
Posted 1/25/2024
Technologies invented and patented by researchers at the Frederick National Laboratory for Cancer Research are on...
Posted 1/9/2024
Research led by the Frederick National Laboratory for Cancer Research (FNL) and Gilead Sciences shows the potential for...
All News
FNL scientists to present multiple studies at American Association for Cancer Research Annual Meeting
Partnership Development OfficePosted 4/13/2023
Investigators from the Frederick National Laboratory for Cancer Research will share their latest work in clinical trials, bioinformatics cancer models, imaging technology initiatives, and more at the American Association for Cancer Research Annual Meeting 2023.
More than 30 abstracts by FNL investigators will be presented in mini symposia and poster sessions…
Experimental flu vaccine shows protection against many strains
Posted 4/4/2023A research group including Frederick National Laboratory scientists has taken an early step toward a universal influenza vaccine that appears to protect against many strains, including the closely watched H5N1 bird flu. Human trials are under way.
Conventional seasonal flu vaccines target the rapidly mutating head of the hemagglutinin (HA) protein on the virus particle, so…
Biotech Connector: Next-Generation Vaccine Formulation and Delivery
Nanotechnology Characterization LaboratoryPosted 3/28/2023Maryland scientists came together earlier this month to discuss next-generation vaccine formulation and delivery, as the Biotech Connector speaker series returned to Frederick.
The Biotech Connector is a quarterly networking and speaker series, hosted by the Frederick National Laboratory for Cancer Research and Frederick County Chamber of Commerce. The scientific event…
Untangling the complex genetics of neurofibromatosis
Protein Expression Laboratory, Advanced Cryo-Electron Microscopy Technology GroupPosted 3/15/2023Severe forms of neurofibromatosis linked to disruptions in a protein partnership
New research by Frederick National Laboratory (FNL) researchers and their colleagues takes an important step toward explaining complex mutations in a gene called NF1 that is known to cause a disorder known as neurofibromatosis type 1. The study also has potential implications in research…
Trends observed in nearly 20 years of nanotech data offer insight
Nanotechnology Characterization LaboratoryPosted 3/7/2023Scientists at Frederick National Laboratory for Cancer Research and the National Cancer Institute have analyzed nearly two decades’ worth of data about biomedical nanotechnology studies, revealing patterns never seen before.
While that may seem exclusively like the domain of laboratory coats and computers, removed from the realm of public concern, its appearance belies…
Women pursuing science add value to the endeavor, with support from mentors and allies
Posted 2/15/2023
To celebrate International Women and Girls in Science Day, we co-hosted a panel discussion on Feb. 10 with Woman to Woman Mentoring and Hood College where successful women in science discussed their chosen career paths, allyship and mentorship in science and strategies for advancement. This was the second annual Women in Science event and the first in-person.
Women…
Looking Back, Looking Ahead: 2022’s AI Symposium Charted Paths for Cancer Research Progress
Bioinformatics and Computational Science, Cancer Data Science InitiativesPosted 2/2/2023
Last year, some of the world’s top leaders in the field came together to discuss the progress of artificial intelligence (AI) applications in cancer research and clinical care at a scientific symposium hosted by Hood College and Frederick National Laboratory (FNL).
It was one of several large scientific gatherings in Frederick in 2022 with implications for the new year…
Encephalitis vaccine does well in early clinical trial; commercial development pending
Vaccine Clinical Materials ProgramPosted 12/21/2022Commercial development of a vaccine against three types of mosquito-borne equine encephalitis viruses — which are classified as potential biological warfare agents and can be fatal in humans — has begun following a government-led phase I clinical trial conducted with materials produced by the Frederick National Laboratory’s Vaccine Clinical Materials Program.
No therapies…
Partnership trainees embrace opportunity for hands-on experience and opt for extended time in FNL laboratories
Partnership Development OfficePosted 12/19/2022Undergraduate and graduate students from academic institutions that partner with the Frederick National Laboratory for Cancer Research gained laboratory experience through the Partnership Trainee Program 2022 summer session, which this year added the Morehouse School of Medicine and the program’s first medical student trainee.
“By welcoming our first medical student, we…
Frederick National Laboratory produces CAR T-cell immunotherapies for pediatric cancer clinical trials
Biopharmaceutical Development ProgramPosted 11/15/2022
The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer-killers that are being used to treat children and young adults participating in early-phase pediatric cancer trials.
The treatment is called chimeric antigen receptor (CAR) T cell therapy. CAR T cells are a type of white blood cell that has been removed…
Media Inquiries
For all media related questions please contact:
Mary Ellen Hackett
Manager, Communications Office